The International Myeloma Foundation (IMF) Launches Medical Student Scholars for Health Equity in Myeloma Mentoring Program
April 20, 2023 08:45 ET
|
International Myeloma Foundation
STUDIO CITY, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) has partnered with the W. Montague Cobb/NMA Health Institute’s Cobb Scholars Program to develop a...
Harpoon Therapeutics to Participate in the Canaccord Horizons in Oncology Conference
April 10, 2023 16:05 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced...
One Community, One Question: What Is Your #MYelomaSTORY?
April 06, 2023 08:45 ET
|
International Myeloma Foundation
STUDIO CITY, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- At the conclusion of this year’s Myeloma Action Month (MAM), the International Myeloma Foundation (IMF) was truly grateful for everyone’s...
The International Myeloma Foundation Announces the Annual Miles for Myeloma 5K Run/Walk: 15 Years of Making a Difference in the Myeloma Community
April 03, 2023 08:45 ET
|
International Myeloma Foundation
PHILADELPHIA, April 03, 2023 (GLOBE NEWSWIRE) -- The Annual Miles for Myeloma Hybrid 5K Run/Walk will once again “Redefine Being Together” on Saturday, April 29, virtually and in-person at FDR Park...
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 27, 2023 16:05 ET
|
Harpoon Therapeutics
HPN217 (BCMA) and HPN328 (DLL3) enrollment on track, with data updates and selection of recommended Phase 2 doses for both active clinical programs planned in 2023 Completion of $25 million...
Harpoon Therapeutics Announces Closing of $25 Million Private Placement
March 27, 2023 16:02 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immuno-oncology company developing novel T cell engagers,...
Multiple Myeloma Market to Exhibit a Remarkable Growth of USD 38.94 Billion by 2029, Size, Share, Trends, Key Drivers, Growth and Opportunity Analysis
March 22, 2023 13:30 ET
|
Data Bridge Market Research
HOUSTON, March 22, 2023 (GLOBE NEWSWIRE) -- Data Bridge Market Research completed a qualitative study titled "Multiple Myeloma Market" with 100+ market data tables, pie charts, graphs, and figures...
Anaveon announces first patient dosed with ANV419 in a Phase I/II Study of ANV419 in patients with multiple myeloma
March 16, 2023 03:00 ET
|
Anaveon
BASEL, Switzerland, March 16, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced the first patient dosed with ANV419 in the OMNIA-2 (ANV419-102) study - a...
International Myeloma Foundation (IMF) Launches #MYelomaSTORY Campaign for Myeloma Action Month in March 2023
February 23, 2023 08:45 ET
|
International Myeloma Foundation
STUDIO CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- With the International Myeloma Foundation (IMF) at the forefront, Myeloma Action Month is held every year for the whole month of March to...
International Myeloma Foundation (IMF) Returns to In-Person Patient and Family Seminars in 2023, Announces Boca Raton Event
February 02, 2023 08:45 ET
|
International Myeloma Foundation
BOCA RATON, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced that this year’s first Patient and Family Seminar is taking place in-person and...